Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)’s traded shares stood at 4.79 million during the last session, with the company’s beta value hitting 1.08. At the close of trading, the stock’s price was $8.85, to imply an increase of 4.86% or $0.41 in intraday trading. The BCRX share’s 52-week high remains $9.50, putting it -7.34% down since that peak but still an impressive 53.56% since price per share fell to its 52-week low of $4.11. The company has a valuation of $1.85B, with an average of 3.86 million shares in intraday trading volume over the past 10 days and average of 3.55 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Biocryst Pharmaceuticals Inc (BCRX), translating to a mean rating of 1.17. Of 13 analyst(s) looking at the stock, 0 analyst(s) give BCRX a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 11 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.05.
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) trade information
After registering a 4.86% upside in the last session, Biocryst Pharmaceuticals Inc (BCRX) has traded red over the past five days. The 5-day price performance for the stock is 11.18%, and 18.00% over 30 days. With these gigs, the year-to-date price performance is 17.69%. Short interest in Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) saw shorts transact 20.44 million shares and set a 6.59 days time to cover.
The extremes give us $7 and $25 for target low and target high price respectively. As such, BCRX has been trading -182.49% off suggested target high and 20.9% from its likely low.
Biocryst Pharmaceuticals Inc (BCRX) estimates and forecasts
The rating firms project that company’s revenue will grow 25.05% compared to the previous financial year.
Revenue forecast for the current quarter as set by 10 analysts is 127.79M. Meanwhile, for the current quarter, a total of 10 analyst(s) estimate revenue growth to 139.08M.Earnings reports from the last fiscal year show that sales brought in 92.76M and 109.33M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 37.76% before jumping 27.21% in the following quarter.
BCRX Dividends
Biocryst Pharmaceuticals Inc has its next earnings report out on 2025-Feb-23. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)’s Major holders
Biocryst Pharmaceuticals Inc insiders hold 1.15% of total outstanding shares, with institutional holders owning 81.12% of the shares at 82.07% float percentage. In total, 81.12% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 19.96 million shares (or 9.6676% of shares), all amounting to roughly $123.33 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 18.77 million shares, or about 9.0926% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $116.0 million.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Biocryst Pharmaceuticals Inc (BCRX) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 6.5 shares. This is just over 3.10% of the total shares, with a market valuation of $57.48 million. Data from the same date shows that the other fund manager holds a little less at 5.43, or 2.59% of the shares, all valued at about 48.02 million.
